Drugs / BJ-005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05115292 | Oct 2021 → Oct 2024 | lymphoma | BJ Bioscience, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BJ-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05115292 ↗ |
| Action | Inhibit | “anti-PD-L1” NCT05115292 ↗ |
| Modality | Monoclonal antibody | “humanized anti-PD-L1 IgG1 monoclonal antibody (mAb)” NCT05115292 ↗ |
| Route | Intravenous | “dosed with intravenous infusion” NCT05115292 ↗ |
| Target | CD274 | “anti-PD-L1” NCT05115292 ↗ |